DBGen second anniversary and summary of the year

DBGen Ocular Genomics is a spin-off of the University of Barcelona specialized in the genetic diagnosis of hereditary eye disorders. It was founded in January 2018 by Roser Gonzàlez-Duarte and Gemma Marfany, both senior scientists focussed in human molecular genetics, particularly in the genetic basis of ocular disorders. DBGen Ocular Genomics aims to provide an […]

DBGen presents a research optimizing the genetic diagnosis of color vision deficiency

DBGen is committed to the quality of genetic diagnosis and its major goal since the beginning of the company is to remain at the forefront of innovation, prioritize resolution of difficult cases, and optimize methodologies that increase the diagnostic yield of inherited ocular diseases. These objectives are clearly attainable due to the high expertise in […]

DBGen presented in the PAAO2019 its most relevant results in the genetic diagnosis of eye diseases in Latin American patients

Dr. Roser Gonzàlez Duarte, professor emeritus of genetics at the University of Barcelona and founder of DBGen, attended the XXXIV Pan-American Congress of Ophthalmology held in Cancun (Mexico) from May 25 to 28, 2019. She presented a paper within the session “Clinical and molecular approaches in hereditary ocular pathologies” coordinated by Dr. Cristina Villanueva, an […]

DBGen and the UB-CIBERER U-718 group present their current research in genetic diagnosis and animal models of inherited retinal dystrophies in ARVO 2019

Dr. Gemma Marfany (co-founder and scientific board member of DBGen) presented an oral communication in ARVO 2019 (held in Vancouver, 2-6 May) to show the most prominent results of the research that his group at the UB-CIBERER (U-718) and DBGEN are currently undertaking to study inherited retinal dystrophies. This work is focused on improved genetic […]

Professor Gemma Marfany has been awarded the distinction of the Council of Doctors and the Board of Trustees of the University of Barcelona for her contribution to scientific communication

LProfessor Gemma Marfany, co-founder and associate director of DBGen Ocular Genomics, has been honored with the Distinction of the Council of Doctors and the Board of Trustees of the University of Barcelona (UB) in its sixth edition. The award ceremony was held on April 2, 2019, in the Aula Magna of the Historic Building of the UB. With […]

We celebrate our first anniversary with a summary of the year

In January 2018, Dr. Roser Gonzàlez-Duarte and Dr. Gemma Marfany founded DBGen Ocular Genomics, a spin-off of the University of Barcelona. Their goal was to approach the genetic diagnosis of ocular hereditary diseases with the highest scientific standards. DBGen Ocular Genomics was born from the experience of more than 25 years of research on the […]

RD2018 Congress discloses new advances and upcoming therapies for Retinal Dystrophies

In September 2018 two relevant meetings related to ocular diseases, the RD2018 International Symposium on Retinal Degeneration and the ISER (International Society for Eye Research) Conference, have taken place in Ireland. In particular, the RD2018 meeting, in which the DBGen team presented two contributions, has focused on the latest advances in genetic diagnosis, disease mechanisms […]

Revolution in Genetic Diagnosis, our contribution to Barraquer magazine

PhD. Roser Gonzàlez and PhD. Gemma Marfany, founders and directors of the company DBGen Ocular Genomics, were invited to participate as columnists of the issue 32 of the Barraquer Ophthalmology Center magazine. Their contribution was dedicated to the genetic diagnosis of inherited eye diseases, emphasizing aspects such as the importance of new technologies: “Massive sequencing of the whole gene or […]

International Women’s Day: Tribute to Marie Gertude Rand

Today, March 8, is the International Women’s Day, a date to commemorate women contribution to science and pay due tribute to Marie Gertrude Rand (1886-1970), an experimental psychologist with outstanding contributions to ophthalmology, physiological optics and lighting instruments design. She received her B.A. (1908) in experimental psychology from Cornell University and her Ph.D. on the […]

LUXTURNA, made available to European patients by Novartis

Spark Therapeutics enters into a licensing agreement with the big pharmaceutical company Novartis to commercialize LUXTURNA, the first gene therapy treatment approved for inherited retinal dystrophies, in Europe. LUXTURNA is addressed to patients suffering from Leber Congenital Amaurosis (LCA) caused by mutations in the RPE65 gene. This one-time gene therapy consists of a subretinal microinjection of therapeutic adenoassociated virus that contain a […]